Drugs that inhibit the activity of the enzyme amino acid decarboxylase, which is responsible for the breakdown of dopamine, are commonly referred to as decarboxylase inhibitors or DC inhibitors. These drugs, such as carbidopa and benserazide, work by blocking the action of the enzyme, thereby preventing the conversion of levodopa (a precursor of dopamine) into dopamine in peripheral tissues. This allows more levodopa to reach the brain, where it can be converted to dopamine and alleviate symptoms in conditions such as Parkinson’s disease.